Funding will support the development of Aurase Wound Gel and progress toward further Phase II clinical trials of innovative wound debriding enzyme CAMBRIDGE, England–(BUSINESS WIRE)–SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing a recombinant enzyme derived from maggots which aims to accelerate wound debridement, has announced the completion of its GBP 10.9m (c. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “The Market for In Vitro Diagnostic (IVD) Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and Other Nations)” report has been added to ResearchAndMarkets.com’s offering. This market report focuses on the market for reagents and instruments in the most important countries of the region. Argentina, Brazil, Chile, Colombia, Mexico, Peru … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “The Market and Future Potential for Molecular Point of Care (mPOC), 2023” report has been added to ResearchAndMarkets.com’s offering. This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular point of care (mPOC) has gone from a novel trend to a significant contributor to the market. … [Read more…]

DUBAI, United Arab Emirates–(BUSINESS WIRE)–Dubai, which is emerging as the wellness and fitness hub of the world is now set to witness Asia’s first ever World Biohack Summit (WBHS) on May 30, 31 – 2023 at Grand Hyatt. Sajeev Nair, co-founder & chairman of Limoverse Technologies, the host of the event said, “This is an … [Read more…]

WILMINGTON, Del. & TOKYO–(BUSINESS WIRE)–$INCY–Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion (also known as 8p11 myeloproliferative syndrome). MLNs are a rare, aggressive group of cancers characterized … [Read more…]

– Short-term safety was confirmed. Efficacy including visual acuity and corneal thickness is improving. TOKYO–(BUSINESS WIRE)–Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”) announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health University and Keio University presented at the 22nd Japanese Society for Regenerative Medicine Annual Conference (Kyoto, Japan, March 23-25, 2023) … [Read more…]

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously … [Read more…]

Moore, who set the course for the future of the semiconductor industry, devoted his later years to philanthropy. SANTA CLARA, Calif.–(BUSINESS WIRE)–Intel and the Gordon and Betty Moore Foundation announced today that company co-founder Gordon Moore has passed away at the age of 94. The foundation reported he died peacefully on Friday, March 24, 2023, … [Read more…]

BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 21, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing … [Read more…]

Patient enrollment underway in Europe in ongoing Phase 2 trial in NSCLC (THIO-101) Outlined plan to initiate second Phase 2 Go-To-Market trial (THIO-102) Presented preclinical data validating efficacy of THIO in hepatocellular carcinoma at SITC Annual Meeting Held pre-IND meeting with FDA for planned U.S. expansion of THIO Advanced new telomere-targeting molecule program CHICAGO–(BUSINESS WIRE)–MAIA … [Read more…]